november AG

euro adhoc: november AG
Financial Figures/Balance Sheet
november AG with positive quarter and nine monthsÂ’ statement on group level Third quarter with improved consolidated and operating result

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

08.11.2005

Erlangen, 08 November 2005. november AG, the development and holding company (ISIN DE0006762909) located in Erlangen, improved its consolidated operating result (EBIT) to -1.616 million EUR by 48% in the first nine months of 2005 compared to previous years reporting period. Thus november AG specialised in bio- and nanotechnology continues the positive trend of the last quarters. On group level revenues increased up to 4.86 million EUR being 28% higher than the last yearÂ’s figure (3.8 million EUR). Due to intensified marketing and distribution activities sales and marketing expenses increased to 1.83 million EUR (prior yearÂ’s reporting period 1.72 million EUR) according to plan. Research and development expenses rose by 7% to 2.27 million EUR as forecasted. The general and administrative expenses could be reduced by 6% to 1.2 million EUR. At the end of the first nine months november AGÂ’s total liquidity was 5.52 million EUR. Total assets on group level amounted to 26.32 million EUR at the end of the third quarter (31.12.04: 27.68 million EUR). Earnings per share (EPS) improved significantly from EUR    -0.26 for the first nine months of 2004 up to EUR  -0.11.  The fully consolidated companies of the november Group engaged from 01.01.2005 to 30.09.2005 on average 61 full time employees.

Annotations  november AG is an Erlangen (Germany) based listed biotech company (Frankfurt Stock Exchange Prime Standard, ISIN DE0006762909, SE symbol NBX) with, inter alia, a focus on development in the field of nanotechnology. Organized as a holding company, the group also includes the subsidiaries identif GmbH (product security & brand protection), directif GmbH (lab independent nucleic acid testing), and PEQLAB Biotechnologie GmbH (biotech R&D supplier). Since 2002, first brand protection products are available with pharma company Bristol-Myers Squibb (Germany) among the first customers. For diagnostics and based on a patented technology, directif GmbH develops the world's first fully integrated nucleic acid testing device which will provide fast and cost-efficient detection of pathogens on the genetic level even at the point of care. On a contractual basis, november will participate in the development of a novel immunotherapeutic approach to fight cancer through profit share options. This new therapy is being developed by responsif GmbH, the former therapeutic business unit of november AG whose management conducted a management buy-out in early 2003.

@@start.t2@@end of announcement                                                 euro adhoc 08.11.2005 09:24:57
--------------------------------------------------------------------------------@@end@@

ots Originaltext: november AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Marcus Weichert
november AG - Public Relations/Investor Relations
Ulrich-Schalk-Str. 3, D-91056 Erlangen
Tel.: +49 (0)9131 750 88 868
e-mail: weichert@november.de, www.november.de

Branche: Biotechnology
ISIN:      DE0006762909
WKN:        676290
Index:    CDAX, Technologie All Share, Prime All Share, Prime Standard
Börsen:  Frankfurter Wertpapierbörse / regulated dealing
              Berliner Wertpapierbörse / free trade
              Baden-WĂĽrttembergische Wertpapierbörse / free trade
              Börse DĂĽsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade
              Bremer Wertpapierbörse (BWB) / free trade



Weitere Meldungen: november AG

Das könnte Sie auch interessieren: